Differentiation of anti-tumour cytotoxic T lymphocytes from autologous peripheral blood lymphocytes in non-Hodgkin's lymphomas

被引:8
作者
Chaperot, L
Manches, O
Mi, JQ
Moine, A
Jacob, MC
Gressin, RM
Molens, JP
Sotto, JJ
Leroux, D
Bensa, JC
Plumas, J
机构
[1] EFS Rhone Alpes, R&D Lab, F-38701 La Tronche, France
[2] Res Grp Lymphomas, Unite UPRES 2021, Grenoble, France
[3] CHU Michallon, Grenoble, France
关键词
lymphoma; CTL; cytotoxicity; PBL; cytokines;
D O I
10.1046/j.1365-2141.2002.03885.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have previously reported that specific antitumour cytotoxic T cells (CTL) can be differentiated from tumour-infiltrating lymphocytes (TIL) in non-Hodgkin's lymphoma. We found that the combination of interleukin (IL)-1, IL-2 and IL-12 was very efficient for expansion of CD8(+) T-cell receptor (TCR)alphabeta(+) T cells and for development of their ability to specifically lyse tumour cells. In this study, we investigated whether anti-tumour T cells could be generated from the peripheral blood of patients using the culture protocol developed for TIL. Autologous T cells and tumour B cells from five patients were included in this study. It was found that polyclonal anti-tumour cytotoxic effector cells were generated when cultured in the presence of IL-1b, IL-2 and IL-12. Interestingly, tumour cells were lysed by perforin/granzyme-mediated cytolysis and not by CD95-mediated apoptosis. By performing inhibition experiments, it was observed that both CD8(+) and CD4(+) T cells were responsible for the cytotoxic effect and that they were able to recognize malignant B cells by either a major histocompatibility complex (MHC)-restricted or MHC-non-restricted mechanism. Intriguingly, in addition to interferon-gamma and tumour necrosis factor-alpha, IL-10 was secreted continuously during culture. The source of patient T cells used for the generation of anti-tumour CTL should be based on the results obtained with peripheral blood lymphocytes and TIL.
引用
收藏
页码:425 / 431
页数:7
相关论文
共 35 条
[1]   Multiple co-stimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue [J].
Agrawal, SG ;
Marquet, J ;
Plumas, J ;
Rouard, H ;
Delfau-Larue, MH ;
Gaulard, P ;
Boumsell, L ;
Reyes, F ;
Bensussan, A ;
Farcet, JP .
INTERNATIONAL IMMUNOLOGY, 2001, 13 (04) :441-450
[2]   INTERFERON-GAMMA AND TUMOR-NECROSIS-FACTOR HAVE A ROLE IN TUMOR REGRESSIONS MEDIATED BY MURINE CD8+ TUMOR-INFILTRATING LYMPHOCYTES [J].
BARTH, RJ ;
MULE, JJ ;
SPIESS, PJ ;
ROSENBERG, SA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (03) :647-658
[3]   Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [J].
Bendandi, M ;
Gocke, CD ;
Kobrin, CB ;
Benko, FA ;
Sternas, LA ;
Pennington, R ;
Watson, TM ;
Reynolds, CW ;
Gause, BL ;
Duffey, PL ;
Jaffe, ES ;
Creekmore, SP ;
Longo, DL ;
Kwak, LW .
NATURE MEDICINE, 1999, 5 (10) :1171-1177
[4]   Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas [J].
Chaperot, L ;
Plumas, J ;
Jacob, MC ;
Bost, F ;
Molens, JP ;
Sotto, JJ ;
Bensa, JC .
EXPERIMENTAL HEMATOLOGY, 1999, 27 (03) :479-488
[5]   From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas [J].
Chaperot, L ;
Jacob, MC ;
Molens, JP ;
Manches, O ;
Bensa, JC ;
Plumas, J .
LEUKEMIA & LYMPHOMA, 2000, 38 (3-4) :247-+
[6]   Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphomas [J].
Chaperot, L ;
Delfau-Larue, MH ;
Jacob, MC ;
Molens, JP ;
Roussel, B ;
Agrawal, S ;
Farcet, JP ;
Gressin, R ;
Sotto, JJ ;
Bensa, JC ;
Plumas, J .
EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) :1185-1193
[7]  
CHEN WF, 1991, J IMMUNOL, V147, P528
[8]   Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10 [J].
Gerosa, F ;
Paganin, C ;
Peritt, D ;
Paiola, F ;
Scupoli, MT ;
AsteAmezaga, M ;
Frank, I ;
Trinchieri, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06) :2559-2569
[9]  
Groux H, 1998, J IMMUNOL, V160, P3188
[10]  
HARRIS NL, 1994, BLOOD, V84, P1361